Inadequate Activation of the GTPase RhoA Contributes to the Lack of Fibronectin Matrix Assembly in von Hippel-Lindau Protein-defective Renal Cancer Cells

被引:14
作者
Feijoo-Cuaresma, Monica [1 ]
Mendez, Fernando [1 ]
Maqueda, Alfredo [2 ]
Esteban, Miguel A. [3 ]
Naranjo-Suarez, Salvador [1 ]
Castellanos, Maria C. [1 ]
Hernandez del Cerro, Mercedes [2 ]
Vazquez, Silvia N. [1 ]
Garcia-Pardo, Angeles [2 ]
Landazuri, Manuel O. [1 ]
Calzada, Maria J. [1 ]
机构
[1] Univ Autonoma Madrid, Dept Med, Hosp Princesa, Serv Immunol, Madrid 28006, Spain
[2] CSIC, Ctr Invest Biol, Dept Fisiopathol Celular & Mol, Madrid 28040, Spain
[3] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510663, Guangdong, Peoples R China
关键词
D O I
10.1074/jbc.M709390200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The von Hippel-Lindau (VHL) tumor suppressor gene regulates extracellular matrix deposition. InVHLnegative renal cancer cells, VHL(-), the lack of fibronectin matrix assembly is thought to promote and maintain tumor angiogenesis allowing vessels to infiltrate tumors. Therefore, and considering the importance of this process in tumor growth, we aimed to study why VHL(-) renal cancer cells fail to form a proper extracellular matrix. Our results showed that VHL(-) cells were not defective in fibronectin production and that the fibronectin produced by these cells was equally functional in promoting cell adhesion and matrix assembly as that produced by VHL(-) cells. We have previously reported that VHL(-) cells fail to form beta 1 integrin fibrillar adhesions and have a diminished organization of actin stress fibers; therefore, we aimed to study if the small GTPase family is involved in this process. We found that activation of the RhoA GTPase was defective in VHL(-) cells, and this was possibly mediated by an increased activation of its inhibitor, p190RhoGAP. Additionally, the expression of constitutively active RhoA in VHL(-) cells resulted in formation of a fibronectin matrix. These results strongly suggest an important role for RhoA in some of the defects observed in renal cancer cells.
引用
收藏
页码:24982 / 24990
页数:9
相关论文
共 56 条
[1]   Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism [J].
Arthur, WT ;
Petch, LA ;
Burridge, K .
CURRENT BIOLOGY, 2000, 10 (12) :719-722
[2]  
Bindra RS, 2002, CANCER RES, V62, P3014
[3]   Fibronectin is a hypoxia-independent target of the tumor suppressor VHL [J].
Bluyssen, HAR ;
Lolkema, MPJK ;
van Beest, M ;
Boone, M ;
Snijckers, CMJT ;
Los, M ;
Gebbink, MFBG ;
Braam, B ;
Holstege, FCP ;
Giles, RH ;
Voest, EE .
FEBS LETTERS, 2004, 556 (1-3) :137-142
[4]  
Calì G, 1999, J CELL SCI, V112, P957
[5]   von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms [J].
Calzada, MJ ;
Esteban, MA ;
Feijoo-Cuaresma, M ;
Castellanos, MC ;
Naranjo-Suárez, S ;
Temes, E ;
Méndez, F ;
Yánez-Mo, M ;
Ohh, M ;
Landázuri, MO .
CANCER RESEARCH, 2006, 66 (03) :1553-1560
[6]   Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease [J].
Clifford, SC ;
Cockman, ME ;
Smallwood, AC ;
Mole, DR ;
Woodward, ER ;
Maxwell, PH ;
Ratcliffe, PJ ;
Maher, ER .
HUMAN MOLECULAR GENETICS, 2001, 10 (10) :1029-1038
[7]   VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling [J].
Davidowitz, EJ ;
Schoenfeld, AR ;
Burk, RD .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (03) :865-874
[8]   Regulation of E-cadherin expression by VHL and hypoxia-inducible factor [J].
Esteban, MA ;
Tran, MGB ;
Harten, SK ;
Hill, P ;
Castellanos, MC ;
Chandra, A ;
Raval, R ;
O'Brien, TS ;
Maxwell, PH .
CANCER RESEARCH, 2006, 66 (07) :3567-3575
[9]   Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein [J].
Esteban, Miguel A. ;
Harten, Sarah K. ;
Tran, Maxine G. ;
Maxwell, Patrick H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (07) :1801-1806
[10]  
Esteban-Barragán MA, 2002, CANCER RES, V62, P2929